10x Genomics (TXG)
(Delayed Data from NSDQ)
$13.13 USD
-0.22 (-1.65%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $13.12 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TXG 13.13 -0.22(-1.65%)
Will TXG be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXG
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Must-Buy Efficient Stocks to Buy Amid Volatile Market Conditions
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
Other News for TXG
Is TXG preparing to trend higher? Crossed Above 50 Day Moving Average shows up after soaring 5.62%
10x Genomics: Surprise Profitability May Be Temporary, But It's Still A Welcome Sign
Is TXG lining up for a decline? MACD Bearish Centerline Cross shows up after sinking 3.22%
Pocket Pivot appears for TXG after 3.73% move
TXG forms 20 Day Moving Average Resistance on September 10